Pfizer takes option on repositioned diabetes drug
This article was originally published in Scrip
The US firm Melior Discovery, which finds new therapeutic applications for existing drugs, has signed an option agreement that provides Pfizerthe exclusive right to negotiate a licence to MLR-1023, Melior's small-molecule drug candidate for type 2 diabetes which is ready for clinical testing. It has previously been shown to be safe in clinical trials, although lackingin efficacy, in another indication. In exchange, Pfizer will make an undisclosed payment to Melior and provide access to certain data it owns related to MLR-1023. In addition, Melior will use its theraTRACE indications discovery platform to evaluate selected Pfizer compounds.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.